New Drug for Moderate to Severe Eczema Treatment
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have moderate to severe atopic dermatitis diagnosed at least 1 year ago that topical treatments haven't controlled well
- Have significant eczema covering at least 10% of your body with intense itching (score of 4 or higher on a 0-10 scale)
- Be at least 18 years old and not pregnant or planning to become pregnant during the study
- Not have HIV, hepatitis B or C, active tuberculosis, or a positive syphilis test
- Not have used any other experimental drugs in the past 30 days
- Not have serious uncontrolled medical conditions like uncontrolled diabetes, heart disease, or severe kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.
This study tests a new drug called BYN-001 in two groups: healthy people and people with moderate to severe eczema (atopic dermatitis). The goal is to see if the drug is safe and how well it works.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Dermatitis, Atopic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.